The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study with immunotherapy with dendritic cells (DC) and intratumoral hiltonol in patients with advanced solid tumors.
José María López-Picazo
No relevant relationships to disclose
Carlos Alfaro
No relevant relationships to disclose
Jose Luis Perez-Gracia
No relevant relationships to disclose
Maria Rodriguez-Ruiz
No relevant relationships to disclose
Alfonso Gurpide
No relevant relationships to disclose
Miguel Fernandez de Sanmamed
No relevant relationships to disclose
Salvador Martin-Algarra
No relevant relationships to disclose
Alberto Benito
No relevant relationships to disclose
David Cano
No relevant relationships to disclose
Alvaro Gonzalez
No relevant relationships to disclose
Inmaculada Rodriguez
No relevant relationships to disclose
Juan Pablo Fusco
No relevant relationships to disclose
Rafael Martinez-Monge
No relevant relationships to disclose
Ignacio Melero
No relevant relationships to disclose